Document Detail


The use of recombinant-activated factor VII in von Willebrand disease: a case series.
MedLine Citation:
PMID:  16651875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Spontaneous and surgery-associated bleeding in patients with von Willebrand disease (vWD) cannot always be controlled with desmopressin or replacement therapy. This paper presents results on the use of recombinant-activated factor VII (rFVIIa) in patients with vWD included in the internet registry Haemostasis.com. Twenty-eight reports on the use of rFVIIa in vWD were identified from the database and included in this analysis. The bleeding episodes were classified as mild (n = 7), moderate (n = 16), or severe (n = 2), and were unspecified in three cases. The median dose of rFVIIa administered was 94 microg/kg body weight (40-127.3 microg/kg). Bleeding stopped in 23 of 27 evaluable patients (85%) and markedly decreased in three patients; the total response rate was 96% (26/27 patients). Response did not correlate with the type of vWD, the site or severity of the initial bleed, or the rFVIIa dose. Other replacement therapies were infrequently used, and their use was similar in the 24 h before and after rFVIIa administration. Eighteen patients also received antifibrinolytic treatment, but its impact on response was not recorded. Only one adverse event (mild fever) was observed. These cases suggest a role for rFVIIa as a safe and effective therapy for vWD.
Authors:
Mario von Depka; Murtada Hassan; Jan Blatnŷ; Petr Smejkal; Vladimir Vdovin
Related Documents :
16091325 - Evaluation of haemostatic function in nigerian norplant acceptors after 12 months of use.
8502095 - Comparison of two methods of tonsillectomy.
10650255 - Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence o...
8578185 - Non-bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazol...
2380095 - Role of intracavitary cuff boost after adjuvant external irradiation in early endometri...
23275385 - Risk stratification and outcome of patients with hypertrophic cardiomyopathy over 60 ye...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  17     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-02     Completed Date:  2007-12-06     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  311-6     Citation Subset:  IM    
Affiliation:
Werlhof-Institute for Haemostasis and Thrombosis, Hannover, Germany. mail@werlhof-institut.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antifibrinolytic Agents / administration & dosage
Child
Child, Preschool
Dose-Response Relationship, Drug
Drug Toxicity
Factor VIII / administration & dosage
Factor VIIa / administration & dosage*,  adverse effects
Female
Follow-Up Studies
Humans
Infant
Male
Middle Aged
Recombinant Proteins / administration & dosage,  adverse effects
Treatment Outcome
von Willebrand Diseases / drug therapy*
Chemical
Reg. No./Substance:
0/Antifibrinolytic Agents; 0/Recombinant Proteins; 9001-27-8/Factor VIII; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of interleukin-6 in fibrinolytic changes induced by lipopolysaccharide in mice.
Next Document:  Use of recombinant activated factor VII to control bleeding in a young child with qualitative platel...